BGB-B167
- Generic Name
- BGB-B167
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05644626
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT05494762
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath